Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright

Enlivex Therapeutics (NASDAQ:ENLV) had its price target raised by HC Wainwright from $6.00 to $7.00 in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $13.00 price target on shares of Enlivex Therapeutics in a research report on Monday, March 3rd.

Enlivex Therapeutics Stock Down 2.4 %

Shares of ENLV stock opened at $1.02 on Monday. The company has a market capitalization of $21.83 million, a P/E ratio of -1.04 and a beta of 1.11. Enlivex Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.59. The firm has a 50-day moving average price of $1.10 and a 200 day moving average price of $1.24.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Two Sigma Securities LLC acquired a new stake in Enlivex Therapeutics in the fourth quarter worth about $26,000. Renaissance Technologies LLC grew its holdings in Enlivex Therapeutics by 112.6% during the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Enlivex Therapeutics in the 4th quarter valued at $742,000. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.